Adiponectin in heart failure

2020 ◽  
Author(s):  
Hubert Mado ◽  
Wioletta Szczurek ◽  
Mariusz Gąsior ◽  
Bożena Szyguła-Jurkiewicz
Keyword(s):  
Heart Failure ◽  
Adipose Tissue ◽  
Cardiovascular Diseases ◽  
Connective Tissue ◽  
Poor Prognosis ◽  
Adiponectin Level ◽  
Endocrine Organ ◽  
Heart Failure Progression ◽  
Severity Of The Disease

The adipose tissue, apart from storing energy, plays a role of an endocrine organ. One of the most important adipokines secreted by adipose tissue is adiponectin, which is also produced by cardiomyocytes and connective tissue cells within the heart. Adiponectin is known for its beneficial effect on the metabolism and cardiovascular system and its low level is a factor of development of many cardiovascular diseases. Paradoxically, in the course of heart failure, adiponectin level gradually increases with the severity of the disease and higher adiponectin level is a factor of poor prognosis. As a result, there is a growing interest in adiponectin as a marker of heart failure progression and a predictor of prognosis in the course of this disease.

scholarly journals Adiponectin in Cardiovascular Inflammation and Obesity

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Tamar R. Aprahamian ◽  
Flora Sam
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Congestive Heart Failure ◽  
Acute Coronary Syndrome ◽  
Adipose Tissue ◽  
Cardiovascular Diseases ◽  
Local Inflammation ◽  
Large Role ◽  
Coronary Syndrome

Inflammation is widely known to play a key role in the development and progression of cardiovascular diseases. It is becoming increasingly evident that obesity is linked to many proinflammatory and obesity-associated cardiovascular conditions (e.g., metabolic syndrome, acute coronary syndrome, and congestive heart failure). It has been observed that adipokines play an increasingly large role in systemic and local inflammation. Therefore, adipose tissue may have a more important role than previously thought in the pathogenesis of several disease types. This review explores the recently described role of adiponectin as an immunomodulatory factor and how it intersects with the inflammation associated with both cardiovascular and autoimmune pathologies.

scholarly journals Role of adipokines in cardiovascular disease

2012 ◽  
Vol 216 (1) ◽  
pp. T17-T36 ◽  
Author(s):  
Harman S Mattu ◽  
Harpal S Randeva
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Cardiovascular Diseases ◽  
Endothelial Function ◽  
White Adipose Tissue ◽  
Endocrine Organ ◽  
New Research ◽  
Chemical Messengers

The discovery of leptin in 1994 sparked dramatic new interest in the study of white adipose tissue. It is now recognised to be a metabolically active endocrine organ, producing important chemical messengers – adipokines and cytokines (adipocytokines). The search for new adipocytokines or adipokines gained added fervour with the prospect of the reconciliation between cardiovascular diseases (CVDs), obesity and metabolic syndrome. The role these new chemical messengers play in inflammation, satiety, metabolism and cardiac function has paved the way for new research and theories examining the effects they have on (in this case) CVD. Adipokines are involved in a ‘good–bad’, yin–yang homoeostatic balance whereby there are substantial benefits: cardioprotection, promoting endothelial function, angiogenesis and reducing hypertension, atherosclerosis and inflammation. The flip side may show contrasting, detrimental effects in aggravating these cardiac parameters.

scholarly journals Adipokines and Inflammation: Focus on Cardiovascular Diseases

2020 ◽  
Vol 21 (20) ◽  
pp. 7711 ◽  
Author(s):  
Sandra Feijóo-Bandín ◽  
Alana Aragón-Herrera ◽  
Sandra Moraña-Fernández ◽  
Laura Anido-Varela ◽  
Estefanía Tarazón ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Risk Factor ◽  
Cardiovascular Diseases ◽  
Low Grade ◽  
Bioactive Substances ◽  
Endocrine Organ ◽  
Adipose Tissue Dysfunction ◽  
Inflammatory Processes ◽  
Regulatory Functions

It is well established that adipose tissue, apart from its energy storage function, acts as an endocrine organ that produces and secretes a number of bioactive substances, including hormones commonly known as adipokines. Obesity is a major risk factor for the development of cardiovascular diseases, mainly due to a low grade of inflammation and the excessive fat accumulation produced in this state. The adipose tissue dysfunction in obesity leads to an aberrant release of adipokines, some of them with direct cardiovascular and inflammatory regulatory functions. Inflammation is a common link between obesity and cardiovascular diseases, so this review will summarise the role of the main adipokines implicated in the regulation of the inflammatory processes occurring under the scenario of cardiovascular diseases.

scholarly journals Adipose tissue as an endocrine organ: role of leptin and adiponectin in the pathogenesis of cardiovascular diseases

2003 ◽  
Vol 59 (1) ◽  
pp. 51-60 ◽  
Author(s):  
A. Fortuño ◽  
A. Rodríguez ◽  
J. Gómez-Ambrosi ◽  
G. Frühbeck ◽  
J. Díez
Keyword(s):  
Adipose Tissue ◽  
Cardiovascular Diseases ◽  
Endocrine Organ

scholarly journals The role of epicardial adipose tissue and autonomic nervous system in pathophysiology of cardiac arrhythmias

2021 ◽  
Vol 25 (3) ◽  
pp. 27
Author(s):  
D. V. Losik ◽  
N. A. Nikitin ◽  
S. M. Minin ◽  
E. V. Fisher ◽  
I. L. Mikheenko ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Nervous System ◽  
Adipose Tissue ◽  
Autonomic Nervous System ◽  
Cardiovascular Diseases ◽  
Cardiac Arrhythmias ◽  
Ventricular Arrhythmias ◽  
Epicardial Adipose Tissue

<p>The role of epicardial adipose tissue (EAT) in the pathogenesis and prognosis of cardiovascular diseases has been actively discussed. This review provides information regarding the main mechanisms by which EAT influences the pathophysiology of rhythm disturbances, such as atrial fibrillation and ventricular arrhythmias, as well as their relationship with chronic heart failure. The pathogenesis of cardiac arrhythmias is exceedingly complex. As such, the mechanism by which EAT influences arrhythmias and heart failure can vary according to the anatomy and type of arrhythmia, one of which involves the autonomic nervous system (ANS). Some studies have shown a good treatment effects by targeting EAT in atrial fibrillation, whereas others have found that EAT volume can be used to predict the efficacy of radiofrequency ablation, a method for treating atrial fibrillation and ventricular arrhythmias. However, no standards have yet been established for the use of EAT visualisation. Fundamental, translational and clinical research are needed to study the role of EAT and ANS in the pathogenesis of cardiovascular diseases.</p><p>Received 15 March 2021. Revised 25 April 2021. Accepted 26 April 2021.</p><p><strong>Funding:</strong> The work is supported by a grant of the Russian Science Foundation (project No. 17-75-20118).</p><p><strong>Conflict of interest:</strong> The authors declare no conflicts of interests.</p><p><strong>Contribution of the authors</strong><br />Conception and study design: D.V. Losik, N.A. Nikitin, S.M. Minin, A.B. Romanov, A.M. Chernyavskiy<br />Drafting the article: D.V. Losik, I.L. Mikheenko, E.V. Fisher, N.A. Nikitin<br />Critical revision of the article: D.V. Losik, I.L. Mikheenko, E.V. Fisher, N.A. Nikitin<br />Final approval of the version to be published: D.V. Losik, N.A. Nikitin, S.M. Minin, E.V. Fisher, I.L. Mikheenko, A.M. Chernyavskiy, A.B. Romanov</p>

scholarly journals The role of systemic inflammation in heart failure

2021 ◽  
Vol 102 (4) ◽  
pp. 510-517
Author(s):  
E V Khazova ◽  
O V Bulashova
Keyword(s):  
Heart Failure ◽  
Cardiovascular Diseases ◽  
Systemic Inflammation ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
C Reactive Protein ◽  
Ventricular Ejection Fraction ◽  
Reactive Protein ◽  
Highly Sensitive

The discussion continues about the role of systemic inflammation in the pathogenesis of cardiovascular diseases of ischemic etiology. This article reviews the information on the role of C-reactive protein in patients with atherosclerosis and heart failure in risk stratification for adverse cardiovascular events, including assessment of factors affecting the basal level of highly sensitive C-reactive protein. Research data (MRFIT, MONICA) have demonstrated a relationship between an increased level of C-reactive protein and the development of coronary heart disease. An increase in the serum level of highly sensitive C-reactive protein is observed in arterial hypertension, dyslipidemia, type 2 diabetes mellitus and insulin resistance, which indicates the involvement of systemic inflammation in these disorders. Currently, the assessment of highly sensitive C-reactive protein is used to determine the risk of developing myocardial infarction and stroke. It has been proven that heart failure patients have a high level of highly sensitive C-reactive protein compared with patients without heart failure. The level of C-reactive protein is referred to as modifiable risk factors for cardiovascular diseases of ischemic origin, since lifestyle changes or taking drugs such as statins, non-steroidal anti-inflammatory drugs, glucocorticoids, etc. reduce the level of highly sensitive C-reactive protein. In patients with heart failure with different left ventricular ejection fraction values, it was found that the regression of the inflammatory response is accompanied by an improvement in prognosis, which confirms the hypothesis of inflammation as a response to stress, which has negative consequences for the cardiovascular system.

Relationship of thyroid dysfunction with cardiovascular diseases: updated review on heart failure progression

HORMONES ◽  
2020 ◽  
Vol 19 (3) ◽  
pp. 301-309
Author(s):  
Adel Abdel-Moneim ◽  
Asmaa M. Gaber ◽  
Sherouk Gouda ◽  
Aya Osama ◽  
Sarah I. Othman ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Diseases ◽  
Thyroid Dysfunction ◽  
Heart Failure Progression ◽  
Relationship Of

scholarly journals COVID-19 in patients with heart failure: the new and the old epidemic

2020 ◽  
Vol 97 (1145) ◽  
pp. 175-179
Author(s):  
Nicolò Sisti ◽  
Serafina Valente ◽  
Giulia Elena Mandoli ◽  
Ciro Santoro ◽  
Carlotta Sciaccaluga ◽  
...  
Keyword(s):  
Heart Failure ◽  
Intensive Care ◽  
Cardiovascular Diseases ◽  
Chronic Heart Failure ◽  
Poor Prognosis ◽  
Myocardial Injury ◽  
Careful Monitoring ◽  
Clinical Challenge ◽  
Patients With Heart Failure ◽  
Acute Decompensation

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has spread in nearly 200 countries in less than 4 months since its first identification; accordingly, the coronavirus disease 2019 (COVID 2019) has affirmed itself as a clinical challenge. The prevalence of pre-existing cardiovascular diseases in patients with COVID19 is high and this dreadful combination dictates poor prognosis along with the higher risk of intensive care mortality. In the setting of chronic heart failure, SARS-CoV-2 can be responsible for myocardial injury and acute decompensation through various mechanisms. Given the clinical and epidemiological complexity of COVID-19, patiens with heart failure may require particular care since the viral infection has been identified, considering an adequate re-evaluation of medical therapy and a careful monitoring during ventilation.

Sign in / Sign up

Export Citation Format

Share Document